Brochure
MENU

Past Tuesday Talks — Exoskeletons & The Freedom to Walk Again

Tuesday, December 12, 2023

Presented by Seema Kumar, CEO, Cure

On this week’s Tuesday Talks, Cure CEO Seema Kumar sat down with Wandercraft CEO, Matthieu Masselin, whose company is using robotics technology to imagine and create a world where mobility knows no bounds. Because of the power of the technology, the product is propelling patients who were struck with spinal cord injuries to stand up and walk again.

Tuesday Talks — Exoskeletons & The Freedom to Walk Again

Topic: A fireside chat to talk using robotics technology to imagine and create a world where mobility knows no bounds.

Speakers: Matthieu Masselin, CEO, Wandercraft. Moderated by Seema Kumar, CEO of Cure

Featured Speakers

About Matthieu Masselin

Graduated from France’s Ecole Polytechnique engineering school (X2008), combined with a Master degree of Science in Engineering from KTH university in Stockholm, Matthieu worked in a research department at Airbus Space & Defense, then on strategic management for the Boston Consulting Group. He joined Wandercraft at its beginnings, leading the command team from 2013, in charge of algorithms & features, before taking on the role of CEO in 2018. In this capacity, he led three successful funding rounds for over 70 M$, established strong relationships with rehabilitation key opinion leaders, and brought Atalante, Wandercraft first product to market through CE Mark. He is now accompanying the strong growth in New York City, developing innovative go-to-market strategies, leading the imminent introduction of Atalante to the US market by preparing for FDA clearance and is already anticipating the future of Wandercraft with the ongoing development of the individual version of the exoskeleton.

Seema Kumar

About Seema Kumar

Seema joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J’s Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company’s external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.